Headlines

Vitamin D and Androgen Receptor-Targeted Therapy Are Effective in Triple-Negative Breast Cancer

Vitamin D and androgen receptor-targeted therapy successfully reduced growth and induced death of cancerous cells in a cell culture model of triple-negative breast cancer.

Consensus Statement Guides Optimal Management of EGFR-Mutation-Positive NSCLC

The 2016 consensus statement from the International Association for the Study of Lung Cancer (IASLC) describes how to best manage EGFR-mutation-positive NSCLC.

Including Proteomics Is Key to Achieving Goals of National Cancer Moonshot

The National Cancer Moonshot needs to target proteins that are driving cancer rather than focusing only on genomics, a new paper suggests.

Vessel-Sparing Radiation Successfully Treats Prostate Cancer, Maintains Quality of Life

Radiation therapy delivered to the critical vessels surrounding the prostate can result in erectile dysfunction and bladder and renal irritation. Vessel-sparing radiation and an improved understanding of the anatomy of the prostate can reduce these effects.

Training Patients With Breast Cancer to Achieve Prolonged Breath Holds Could Improve Targeted Radiotherapy

Patients with breast cancer can be trained to achieve a breath hold lasting more than 5 minutes, allowing for targeted administration of radiotherapy with a single dose per daily session that can minimize damage to surrounding tissues.

Drug Candidate Successful in Targeting Cancer-Causing RNA

A new drug candidate reduced the growth of tumors in a mouse model of triple negative breast cancer (TNBC) by targeting the RNA, or expression, of a gene only expressed in the diseased cells.

Adhering to Patient Preferences Improves Patient Comfort During Skin Cancer Screening

To improve patient comfort during full-body skin cancer screenings, dermatologists should respect patients' preferences for the gender of the examining clinician and for how the genital area is examined.

Including Quality Measures In Treatment Regimens Increases Survival in Stage IIIA Non-Small Cell Lung Cancer

Including Quality Measures In Treatment Regimens Increases Survival in Stage IIIA Non-Small Cell Lung Cancer

When more quality measures are incorporated into patient care, survival rates for patients with stage IIIA non-small cell lung cancer (NSCLC) increase, but only 13% of eligible patients actually receive all 4 recommended quality measures.

New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening

New Research Questions Recommendations Regarding PSA Tests for Prostate Cancer Screening

New research results favor testing for prostate specific antigen (PSA) levels for detection of prostate cancer. PSA tests can reduce the number of fatal cases of prostate cancer by detecting disease early.

Genetic Biomarker Predictive of Peripheral Neuropathy in Patients Receiving Docetaxel for Prostate Cancer

Docetaxel-induced neuropathy may be predicted by single nucleotide polymorphisms in VAC14.

Conference Coverage

Radiation Therapy Better Than Chemotherapy for Stage IIA Testicular Cancer

Patients with stage IIA testicular cancer gain a survival advantage from treatment with radiation therapy compared with chemotherapy.

Increased Risk of Noncancer Deaths Associated with Stereotactic Body Radiation Therapy for Lung Cancer

High doses of SBRT, particularly to the left atrium of the heart and the superior vena cava, are associated with a small but increased risk of death from noncancer causes in patients with early stage NSCLC.

Immunotherapy-radiation Combination Destroys Tumors Both Within and Outside the Radiation Field

Adding an immune system-strengthening compound to radiation therapy can extend the immune response that the radiation therapy induces, so that both irradiated tumor sites and tumors outside the radiation field are affected.

Survival in Head and Neck Cancer Increased With Nivolumab Over Chemotherapy

The immunotherapy drug nivolumab conferred a survival benefit in patients with head and neck cancer over standard chemotherapy.

New Drug Combination Before Surgery May Improve Outcomes for Advanced HER2+ Breast Cancer

Combining trastuzumab emtansine (T-DM1) and pertuzumab before surgery was more beneficial than the combination of paclitaxel plus trastuzumab for patients with HER2-positive invasive breast cancer.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs